MX2016012419A - Formas solidas de ibrutinib y procesos para la produccion de las mismas. - Google Patents

Formas solidas de ibrutinib y procesos para la produccion de las mismas.

Info

Publication number
MX2016012419A
MX2016012419A MX2016012419A MX2016012419A MX2016012419A MX 2016012419 A MX2016012419 A MX 2016012419A MX 2016012419 A MX2016012419 A MX 2016012419A MX 2016012419 A MX2016012419 A MX 2016012419A MX 2016012419 A MX2016012419 A MX 2016012419A
Authority
MX
Mexico
Prior art keywords
ibrutinib
production process
solid forms
forms
process therefor
Prior art date
Application number
MX2016012419A
Other languages
English (en)
Inventor
Adin Itai
KERIVONOS Sonia
Rozenblat Yevgeny
WEISMAN Alex
TEN FIGAS Gloria
Fernadez Casares Ana
Ben-Daniel Revital
Original Assignee
Perrigo Api Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perrigo Api Ltd filed Critical Perrigo Api Ltd
Publication of MX2016012419A publication Critical patent/MX2016012419A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se proporcionan polimorfos de ibrutinib, por ejemplo, las formas III, IV, V, VI, VII, VII y la Forma IX de ibrutinib cristalino y los procesos para producir estas formas cristalinas, ibrutinib amorfo estable y los procesos 5 para preparar el ibrutinib amorfo estable, composiciones farmac?uticas que comprenden estas formas y m?todos para usar estas formas cristalinas y amorfas.
MX2016012419A 2014-03-27 2015-03-23 Formas solidas de ibrutinib y procesos para la produccion de las mismas. MX2016012419A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971164P 2014-03-27 2014-03-27
US201462045869P 2014-09-04 2014-09-04
PCT/IL2015/000017 WO2015145415A2 (en) 2014-03-27 2015-03-23 Ibrutinib solid forms and production process therefor

Publications (1)

Publication Number Publication Date
MX2016012419A true MX2016012419A (es) 2016-11-30

Family

ID=54196519

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012419A MX2016012419A (es) 2014-03-27 2015-03-23 Formas solidas de ibrutinib y procesos para la produccion de las mismas.

Country Status (7)

Country Link
US (2) US9884869B2 (es)
EP (1) EP3122753A4 (es)
AU (1) AU2015237744A1 (es)
CA (1) CA2941087A1 (es)
IL (1) IL247963A0 (es)
MX (1) MX2016012419A (es)
WO (1) WO2015145415A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CN106573002A (zh) 2014-08-07 2017-04-19 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的新型制剂
WO2016079216A1 (en) * 2014-11-20 2016-05-26 Sandoz Ag Physical forms of ibrutinib, a bruton's kinase inhibitor
WO2016139588A1 (en) * 2015-03-03 2016-09-09 Dr. Reddy's Laboratories Limited Polymorphs of ibrutinib
BR122023020985A2 (pt) 2015-03-03 2023-12-26 Pharmacyclics Llc Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton
WO2017029586A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Crystalline forms of ibrutinib
US9834561B2 (en) 2015-10-28 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing ibrutinib and its intermediates
CN105622614B (zh) * 2015-12-18 2021-02-26 重庆医药工业研究院有限责任公司 一种依鲁替尼无定型物及其制备方法
CN106905320A (zh) * 2015-12-23 2017-06-30 杭州容立医药科技有限公司 一种适合药用的依鲁替尼及其制剂
CN106995445B (zh) * 2016-01-22 2021-08-03 山东新时代药业有限公司 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法
WO2017134588A1 (en) 2016-02-04 2017-08-10 Shilpa Medicare Limited Process for the preparation of ibrutinib
GB2558514A (en) * 2016-02-09 2018-07-18 Azad Pharmaceutical Ingredients Ag Process for the synthesis of stable amorphous ibrutinib
CN105646498A (zh) * 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型f及制备方法
CN105646499A (zh) * 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型g及制备方法
CN107286163A (zh) * 2016-03-30 2017-10-24 上海星泰医药科技有限公司 一种依鲁替尼的新晶型及其制备方法
CZ2016196A3 (cs) 2016-04-06 2017-10-18 Zentiva, K.S. Pevné formy Ibrutinibu
CZ2016276A3 (cs) 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
CN106008529A (zh) * 2016-08-08 2016-10-12 上海工程技术大学 一种依鲁替尼溶剂化物及其制备方法
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company NEW FORMS OF IBRUTINIB
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
WO2019211870A1 (en) 2018-05-02 2019-11-07 Cipla Limited Polymorphic forms of ibrutinib
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
CN113135917A (zh) * 2020-01-16 2021-07-20 北京赛思源生物医药技术有限公司 一种依鲁替尼的无定型物及其药用组合物
CN112630346B (zh) * 2020-12-16 2022-11-01 河北合佳医药科技集团股份有限公司 一种伊布替尼中残留溶剂的定量分析方法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53165B (en) 2007-03-14 2014-06-30 Bionsil S.R.L. BTK INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT EPITHELIC TUMORS
JP5369183B2 (ja) 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
WO2014004707A1 (en) * 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法

Also Published As

Publication number Publication date
EP3122753A4 (en) 2017-11-29
US9884869B2 (en) 2018-02-06
US10280173B2 (en) 2019-05-07
AU2015237744A1 (en) 2016-09-15
CA2941087A1 (en) 2015-10-01
US20170226108A1 (en) 2017-08-10
EP3122753A2 (en) 2017-02-01
WO2015145415A2 (en) 2015-10-01
IL247963A0 (en) 2016-11-30
WO2015145415A3 (en) 2015-11-19
US20180251463A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
MX2016012419A (es) Formas solidas de ibrutinib y procesos para la produccion de las mismas.
PH12020550246A1 (en) Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3266743A4 (en) Method for preparing biomass graphene by using cellulose as raw material
IN2014CH00247A (es)
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
IL275111A (en) A process for preparing a preparation of transgenic T cells
ZA201604838B (en) Process for the production of synthesis gas
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
IN2013MU00646A (es)
IN2014MU00455A (es)
ZA201604873B (en) Process for producing synthesis gas
MA40312A (fr) Composition pharmaceutique orale d'isotrétinoïne
ZA201801650B (en) Process for producing novel 4-benzoazonine derivatives
EP3498805A4 (en) METHOD FOR PRODUCING MODIFIED TEER
IN2014CH00444A (es)
ZA201907427B (en) Process for hydrogen production
EP3133164A4 (en) Method for producing chemical substance by continuous fermentation
EP3166885A4 (en) Process for producing hydrogen
IN2015CH00214A (es)
MY187078A (en) Process of production of 7,8-dihydro-c15-aldehyde
PL3234100T3 (pl) Bioreaktor i sposób fermentacji do produkcji wodoru
EP3124469A4 (en) Process for producing 1-arylimino-2-vinylcyclopropanecarboxylic acid derivative
IN2012CH02984A (es)
PH12017500220A1 (en) Method for obtaining crystalline l-alanine